KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得

High-frequency irreversible electroporation versus transurethral resection of the prostate for benign prostatic hyperplasia (GIANT): a single-centre, randomised, double-blind, phase 3, non-inferiority trial.

Bi-Ming He, Rong-Bing Li, Dong-Yang Li, Li-Qun Huang, Zhi-Chao Jin, Zhen-Kai Shi, Shuai-Dong Wang, Jia-Sun Lu, Ji-Ling Wen, Hai-Feng Wang

EClinicalMedicine 97 104034

PMID42433275
PMCIDPMC13352031
DOI10.1016/j.eclinm.2026.104034
发表日期2026-07-11
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:图注未提示 KM 曲线;Fig. 2:森林图/亚组分析图。
摘要

摘要

BACKGROUND: Transurethral resection of the prostate (TURP) is the gold standard for treating benign prostatic hyperplasia (BPH) but frequently causes retrograde ejaculation and bleeding. High-frequency irreversible electroporation (H-FIRE) is a non-thermal ablation technique offering tissue selectivity. We aimed to compare the efficacy and safety of H-FIRE versus TURP in men with symptomatic BPH. METHODS: In this investigator-initiated, single-centre, randomised, double-blind, non-inferiority trial at Shanghai East Hospital, China, men aged 40 years or older with symptomatic BPH (prostate volume 30-100 mL) were assigned (1:1) to undergo H-FIRE or TURP. To maintain blinding, a sham protocol involving perineal dressings and standardised irrigation was used. The co-primary outcomes were change from baseline in maximum urinary flow rate (Qmax) and International Prostate Symptom Score (IPSS) at 3 months. Non-inferiority margins were -4 mL/s for Qmax and 3 points for IPSS. Efficacy was analysed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT05306145. FINDINGS: Between June 30, 2022, and May 25, 2025, 118 participants were enrolled and randomly assigned to H-FIRE (n = 59) or TURP (n = 59). H-FIRE was non-inferior to TURP for both primary endpoints: mean Qmax improvement was 7.95 mL/s with H-FIRE versus 7.84 mL/s with TURP (adjusted difference 0.11 mL/s, 95% CI -2.52 to 2.73; p = 0.001 for non-inferiority); mean IPSS reduction was -13.24 versus -13.75 (adjusted difference 0.50, -1.09 to 2.10; p = 0.001 for non-inferiority). Retrograde ejaculation occurred in 0% (0/59) of patients in the H-FIRE group compared with 54.2% (32/59) in the TURP group (p < 0.0001). H-FIRE was associated with greater haemodynamic stability (mean haemoglobin change +0.82 g/L [95% CI -1.84 to 3.48] versus -12.14 g/L [-14.72 to -9.55]; p < 0.0001) but required longer postoperative catheterisation (median 19 days [IQR 15.0-22.0] versus 4 days [4.0-5.0]). There were no grade 3-4 adverse events, and no deaths occurred in either group. INTERPRETATION: At 3 months, H-FIRE provided short-term functional improvement non-inferior to TURP while completely preserving ejaculatory function and minimising blood loss. Although associated with longer temporary catheterisation due to tissue resorption, H-FIRE represents a viable function-sparing alternative for men prioritising sexual health and offers potential for ambulatory management. FUNDING: National Natural Science Foundation of China (No. 82373048) and National Natural Science Foundation of China for Youth (No. 82303612).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Trial profile .
非 KM Figure
Fig. 2Fig. 2 Non-inferiority analysis of the primary outcomes at 3 months. The forest plot displays the adjusted differences (H-FIRE minus TURP) in the change from baseline for Qmax (A) and Total IPSS (B) . The solid squares represent the point estimates of the difference, and the horizontal bars represent the 95% CIs. The vertical dashed lines indicate the prespecified non-inferiority margins (−4.0 mL/s for Qmax; +3.0 points for IPSS).
非 KM Figure